<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology and classification of central nervous system tumors in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology and classification of central nervous system tumors in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology and classification of central nervous system tumors in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ching Lau, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wan-Yee Teo, MBBS, FAAP, MRCPCH (UK), FRCP Edin, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David G Poplack, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central nervous system (CNS) tumors include both nonmalignant and malignant tumors of the brain and spinal cord. Primary malignant CNS tumors are the second most common childhood malignancies after hematologic malignancies and are the most common pediatric solid organ tumor  (
         <a class="graphic graphic_table graphicRef99680" href="/z/d/graphic/99680.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. Although progress has been made in the treatment of childhood tumors, significant mortality and morbidity are still associated with malignant brain tumors.
        </p>
        <p>
         The epidemiology of CNS tumors in children will be reviewed here. The clinical manifestations, diagnosis, and overview of the management of CNS tumors and outcome in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6250.html" rel="external">
          "Clinical manifestations and diagnosis of central nervous system tumors in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6253.html" rel="external">
          "Overview of the management of central nervous system tumors in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States from 2015 to 2019, the average annual incidence of primary nonmalignant and malignant CNS tumors for children and adolescents ≤19 years of age was 6.3 cases per 100,000 population [
         <a href="#rid4">
          4
         </a>
         ]. Approximately 58 percent of cases were malignant and 42 percent were nonmalignant. Somewhat lower incidence rates have been reported in other parts of the world, including Japan (estimated incidence 3.61 per 100,000 children) [
         <a href="#rid5">
          5
         </a>
         ], Italy (3.46 per 100,000 children) [
         <a href="#rid6">
          6
         </a>
         ], Germany (2.6 per 100,000 children) [
         <a href="#rid7">
          7
         </a>
         ], Australia (3 per 100,000 children) [
         <a href="#rid8">
          8
         </a>
         ], and Taiwan (1.7 per 100,000 children) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         In the United States, CNS tumors are the most common solid tumors in children  (
         <a class="graphic graphic_table graphicRef99680" href="/z/d/graphic/99680.html" rel="external">
          table 1
         </a>
         ) and a leading cause of cancer death in children 0 through 14 years [
         <a href="#rid1">
          1,4,10,11
         </a>
         ]. Malignant CNS tumors account for approximately 15 to 20 percent of all childhood malignancies  (
         <a class="graphic graphic_table graphicRef99680" href="/z/d/graphic/99680.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The incidence of childhood CNS tumors varies with age, sex, race, and ethnicity [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – The incidence of childhood CNS tumors varies with age. In a report from the Central Brain Tumor Registry of the United States (CBTRUS; 2015 to 2019), the following overall annual age-adjusted incidence rates of CNS tumors per 100,000 population were reported [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 0 to 4 years – 6.03 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 5 to 9 years – 5.47 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 10 to 14 years – 5.88 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 15 to 19 years – 7.40 per 100,000
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex
         </strong>
         – The rate is higher in males compared with females [
         <a href="#rid1">
          1,4,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Race and ethnicity
         </strong>
         – The incidence of CNS tumors per 100,000 population in CBTRUS is greatest in White American and Asian/Pacific Islander children [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         White Americans – 6.39 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Black Americans – 4.89 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asian/Pacific Islanders – 3.47 per 100,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         American Indians/Alaska Natives – 3.47 per 100,000
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          TRENDS OVER TIME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incidence rate increased for all age groups from 1975 to 1980 and 1987 to 1992. This change in incidence did not occur progressively from 1975 to 1994 but jumped to a higher rate after 1985. This increase has been attributed to the increased availability of magnetic resonance imaging (MRI), which likely resulted in improved diagnostic sensitivity rather than an actual increase in incidence [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two main classification systems are used to categorize childhood CNS tumors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         World Health Organization (WHO) classification is based on tumor histology and molecular parameters
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         International Classification of Childhood Cancer (ICCC) is based on the primary tumor site and morphology
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          World Health Organization classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         WHO classification for CNS tumors, which has been universally adopted in grouping CNS tumors, was first published in 1979 and subsequently revised five times, most recently in 2021 [
         <a href="#rid15">
          15
         </a>
         ]. The 2021 WHO classification introduces major changes that advance the role of molecular diagnostics in CNS tumor classification and emphasizes the importance of integrated diagnoses  (
         <a class="graphic graphic_algorithm graphicRef134946" href="/z/d/graphic/134946.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The classification of gliomas is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H833805431">
         <span class="h2">
          Distribution by tumor type
         </span>
         <span class="headingEndMark">
          —
         </span>
         The relative frequencies of different tumor types vary with age. The distribution in children differs from that in adults  (
         <a class="graphic graphic_figure graphicRef70767" href="/z/d/graphic/70767.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef61480" href="/z/d/graphic/61480.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. In children, primary CNS tumors predominate and approximately one-third to one-half are located in the posterior fossa  (
         <a class="graphic graphic_figure graphicRef81514" href="/z/d/graphic/81514.html" rel="external">
          figure 3
         </a>
         ). By contrast, CNS tumors in adults are often metastatic lesions to the cerebral cortex. These differences translate to differences in clinical presentation between pediatric and adult malignant CNS tumors. (See
         <a class="medical medical_review" href="/z/d/html/6250.html" rel="external">
          "Clinical manifestations and diagnosis of central nervous system tumors in children"
         </a>
         .)
        </p>
        <p>
         The following sections provide brief summaries of epidemiologic data on selected childhood malignant and nonmalignant CNS tumor types, each of which is discussed in greater detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gliomas
         </strong>
         – The 2021 WHO classification is the first to separate diffuse gliomas that primarily occur in children from those that primarily occur in adults, recognizing the clinically and biologically distinct nature of these groups [
         <a href="#rid15">
          15
         </a>
         ]. Gliomas account for approximately one-half of all CNS tumors in children and adolescents [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Circumscribed astrocytomas
         </strong>
         – Several astrocytic gliomas are relatively indolent lesions, which are more circumscribed than the diffuse gliomas. All occur primarily in children. Among these, pilocytic astrocytoma is the most common, with an incidence of approximately 1 per 100,000 population  (
         <a class="graphic graphic_diagnosticimage graphicRef78521" href="/z/d/graphic/78521.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Other astrocytic tumors in this category include high-grade astrocytoma with piloid features, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma (SEGA), chordoid glioma, and astroblastoma,
         <em>
          MN1
         </em>
         -altered. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Circumscribed astrocytic gliomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pediatric-type diffuse low-grade gliomas
         </strong>
         – Four pediatric-type diffuse gliomas are recognized  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 2
         </a>
         ). Three of the four are WHO grade 1 tumors that typically occur in infants or young children and can be cured by surgery alone. Molecular alterations in the mitogen-activated protein kinase (MAPK) pathway define the fourth tumor in this group, which are low-grade gliomas with diffuse astrocytic or oligodendroglial morphology. (See
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Pediatric-type diffuse low-grade gliomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pediatric-type diffuse high-grade gliomas
         </strong>
         – High-grade gliomas in children are divided into diffuse midline glioma, H3 K27-altered (which includes most diffuse intrinsic pontine gliomas); diffuse hemispheric glioma, H3 G34-altered; diffuse high-grade glioma, H3- and isocitrate dehydrogenase (IDH)-wildtype; and infant-type hemispheric glioma  (
         <a class="graphic graphic_table graphicRef134980" href="/z/d/graphic/134980.html" rel="external">
          table 2
         </a>
         ). These highly malignant and aggressive tumors carry an extremely poor prognosis. (See
         <a class="medical medical_review" href="/z/d/html/5229.html" rel="external">
          "Diffuse intrinsic pontine glioma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5211.html" rel="external">
          "Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Pediatric-type diffuse high-grade gliomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ependymomas
         </strong>
         – Ependymal tumors are derived from primitive glia  (
         <a class="graphic graphic_table graphicRef109513" href="/z/d/graphic/109513.html" rel="external">
          table 4
         </a>
         ). Ependymomas account for 10 percent of intracranial tumors and 40 to 60 percent of spinal cord tumors in children and young adults, with a reported incidence of 0.3 per 100,000 population [
         <a href="#rid2">
          2,17
         </a>
         ]. In children, approximately 90 percent of ependymomas are intracranial (60 percent in the posterior fossa); the remaining tumors arise within the spinal cord. In children &lt;3 years of age, ependymomas are typically posterior fossa tumors located about or within the fourth ventricle  (
         <a class="graphic graphic_diagnosticimage graphicRef53610" href="/z/d/graphic/53610.html" rel="external">
          image 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5224.html" rel="external">
          "Intracranial ependymoma and other ependymal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medulloblastoma
         </strong>
         – Medulloblastoma is one of the most common malignant brain tumors of childhood  (
         <a class="graphic graphic_table graphicRef109467" href="/z/d/graphic/109467.html" rel="external">
          table 3
         </a>
         ). It accounts for approximately 6 to 7 percent of all pediatric CNS tumors (malignant and nonmalignant) [
         <a href="#rid2">
          2
         </a>
         ]. It occurs primarily in the cerebellum  (
         <a class="graphic graphic_diagnosticimage graphicRef55787" href="/z/d/graphic/55787.html" rel="external">
          image 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5219.html" rel="external">
          "Clinical presentation, diagnosis, and risk stratification of medulloblastoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Embryonal tumors
         </strong>
         – Excluding medulloblastoma, other embryonal CNS tumors include atypical teratoid rhabdoid tumors, embryonal tumor with multilayered rosettes, forkhead box R2 (
         <em>
          FOXR2
         </em>
         )-activated CNS neuroblastoma, and CNS tumor with BCL6 corepressor (
         <em>
          BCOR
         </em>
         ) internal tandem duplication  (
         <a class="graphic graphic_table graphicRef111773" href="/z/d/graphic/111773.html" rel="external">
          table 5
         </a>
         ). In addition, some tumors previously diagnosed as CNS primitive neuroectodermal tumor (PNET) remain in a category referred to as CNS embryonal tumor, not otherwise specified (NOS). Embryonal tumors are highly malignant brain tumors associated with a very poor prognosis. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Embryonal tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumors of the sellar region
         </strong>
         – Tumors of the sellar region include pituitary tumors and craniopharyngiomas. These tumors are generally located in the suprasellar area and arise from remnants of Rathke pouch. Together, they account for approximately 15 percent of all pediatric CNS tumors [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">
          "Causes, presentation, and evaluation of sellar masses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">
          "Craniopharyngioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glioneuronal and neuronal tumors
         </strong>
         – Glioneuronal and neuronal tumors are characterized by a variable degree of neuronal differentiation  (
         <a class="graphic graphic_table graphicRef109517" href="/z/d/graphic/109517.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. They include gangliomas and gangliocytomas, dysplastic gangliogliocytoma of the cerebellum (Lhermitte-Duclos disease), cerebellar liponeurocytomas, central neurocytomas, and glomus tumors (paragangliomas). They account for approximately 7 percent of all pediatric CNS tumors [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Glioneuronal and neuronal tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumors of cranial and paraspinal nerves
         </strong>
         – Tumors of cranial and paraspinal nerves include schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors. They account for approximately 5 percent of all pediatric CNS tumors [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5196.html" rel="external">
          "Intradural nerve sheath tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Germ cell tumors
         </strong>
         – Germ cell tumors include germinoma, embryonal carcinoma, yolk sac tumor (endodermal sinus tumors), choriocarcinoma, and teratoma. They account for approximately 3 to 4 percent of all pediatric CNS tumors [
         <a href="#rid2">
          2
         </a>
         ]. Approximately two-thirds of these tumors occur in the pineal and suprasellar areas, and the remaining occur in the supratentorial region.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meningiomas
         </strong>
         – Tumors of the meninges arise from the arachnoidal cap cell in the arachnoid membrane and have varying degrees of malignancy. They account for approximately 2 to 3 percent of all pediatric CNS tumors [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5220.html" rel="external">
          "Epidemiology, pathology, clinical features, and diagnosis of meningioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphomas
         </strong>
         – Lymphoma and hemopoietic neoplasms account for a very small proportion of CNS tumors in children (&lt;1 percent of all pediatric CNS tumors) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unclassified tumors
         </strong>
         – Unclassified tumors include hemangiomas and other unspecified neoplasms [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The data described above reflect the distribution of the different tumor types in pediatric patients in the United States. The distribution may differ in other populations. For example, in a retrospective study of 1485 cases of primary CNS tumors in children cared for at a single neurosurgical center in China between 2001 and 2005, the five most common brain tumors were [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Astrocytic tumors (31 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Craniopharyngiomas (18 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medulloblastoma (15 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Germ cell tumors (8 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ependymal tumors (6 percent)
        </p>
        <p>
        </p>
        <p>
         In the same report, the most common spinal cord tumors were ependymal tumors (19 percent), schwannomas (17 percent), and astrocytomas (15 percent) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          International Classification of Childhood Cancer classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICCC is based upon primary tumor site and is used by the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute in their epidemiologic survey of childhood cancer in the United States.
        </p>
        <p>
         In this classification schema, tumors are categorized by site of origin, separating brain tumors from spine and cranial nerve tumors. Tumors are then further subdivided into histologic groups: ependymoma, astrocytoma, PNET, other gliomas, and miscellaneous.
        </p>
        <p>
         A limitation of the ICCC classification is that mortality rates for tumors based upon their underlying histology cannot be identified, because the initial categorization is based on site. As an example, astrocytomas of the spinal cord would not be categorized with brain astrocytomas.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Distribution by site
         </span>
         <span class="headingEndMark">
          —
         </span>
         The location of the tumor may impact the clinical presentation. As an example, vision loss may occur with any tumor that is localized along the optic pathway. Infratentorial tumors may present with localizing signs of ataxia or cranial neuropathies. (See
         <a class="medical medical_review" href="/z/d/html/6250.html" rel="external">
          "Clinical manifestations and diagnosis of central nervous system tumors in children", section on 'Tumor location'
         </a>
         .)
        </p>
        <p>
         The distribution of CNS tumors by site based on Central Brain Tumor Registry of the United States (CBTRUS) data is shown in the figure  (
         <a class="graphic graphic_figure graphicRef81514" href="/z/d/graphic/81514.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In the previously mentioned Chinese report of 1485 primary CNS tumors, 92 percent were located in the brain and 8 percent were located in the spinal cord. Sixty-two percent of the brain tumors were supratentorial.
        </p>
        <p>
         Because spinal cord tumors are relatively rare, it is difficult to ascertain the relative frequency of specific tumors. In one case series of 35 children with a spinal cord tumor, 11 patients had neurodevelopmental tumors (ie, dermoid and epidermoid tumors, and teratomas), followed by 10 with astrocytoma, and 5 with neuroblastoma [
         <a href="#rid18">
          18
         </a>
         ]. Other causes of spinal tumors included schwannoma, meningioma, giant cell tumors, extradural cystic masses, leukemic-related masses, and masses associated with neurofibromatosis (NF).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the etiology of most childhood CNS tumors remains unknown, two established risk factors for the development of a CNS tumor include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exposure to ionizing radiation
         </strong>
         − Cranial irradiation results in an increased risk of developing meningiomas, gliomas, and nerve sheath tumors [
         <a href="#rid19">
          19
         </a>
         ]. In particular, high-dose cranial irradiation in patients with acute lymphoblastic leukemia is associated with a 6- and 10-fold increase in the risk of glioma and meningioma, respectively. (See
         <a class="medical medical_review" href="/z/d/html/6247.html" rel="external">
          "Acute lymphoblastic leukemia/lymphoblastic lymphoma: Outcomes and late effects of treatment in children and adolescents", section on 'Brain tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5214.html" rel="external">
          "Risk factors for brain tumors", section on 'Ionizing radiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic predisposition
         </strong>
         − Many pediatric patients with CNS tumors have a genetic predisposition. In a study that used next-generation sequencing to determine the contribution of germline predisposition mutations in 1120 children with cancer, mutations that were deemed to be pathogenic or probably pathogenic were identified in 20 of 245 patients (8 percent) with CNS tumors [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Genetic syndromes that confer an increased risk of developing tumors of the nervous system include the following genetic conditions, which are discussed in greater detail separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neurofibromatosis (NF) is an autosomal dominant neurocutaneous disorder, which includes NF type 1 (also known as von Recklinghausen disease) and NF type 2. Both are associated with CNS tumors. (See
         <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">
          "Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5206.html" rel="external">
          "
          <i>
           NF2
          </i>
          -related schwannomatosis (formerly neurofibromatosis type 2)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tuberous sclerosis is an autosomal dominant neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including multiple benign neoplasms of the brain, kidney, and skin. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features", section on 'Brain lesions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Von Hippel-Lindau disease is an autosomal dominant disorder associated with hemangioblastomas, pancreatic cysts, neuroendocrine tumors, renal tumors, and pheochromocytomas. (See
         <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">
          "Clinical features, diagnosis, and management of von Hippel-Lindau disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">
          "Molecular biology and pathogenesis of von Hippel-Lindau disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basal cell nevus syndrome, also referred to as Gorlin syndrome or nevoid basal cell cancer syndrome, is caused by germline mutations of the patched 1 (
         <em>
          PTCH
         </em>
         ) gene, a tumor suppressor gene. It is associated with an increased risk of medulloblastoma. (See
         <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">
          "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Li-Fraumeni syndrome is an autosomal dominant disorder characterized by soft tissue and bone sarcomas, breast cancers, and other malignancies, including brain tumors, leukemia, and adrenocortical cancer. (See
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Turcot syndrome is a disorder that includes brain tumors (primarily medulloblastomas and gliomas) and one of two forms of colonic polyposis. (See
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis", section on 'Extracolonic manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Maternal exposure to drugs during pregnancy is of interest as a risk factor for childhood brain tumors and other cancers, but existing data are limited and inconclusive [
         <a href="#rid21">
          21
         </a>
         ]. In a case-control study of 280 childhood brain tumor cases and over 900 matched controls that used maternal interviews to assess fetal exposure to a variety of medication classes, maternal use of immunosuppressant medications was associated with increased risk of glial tumors (odds ratio 2.73, 95% CI 1.17-6.39) [
         <a href="#rid22">
          22
         </a>
         ]. This finding warrants further study, as maternal blood and immune disorders have been identified as a potential risk factor in at least one other epidemiologic study [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2291696614">
         <span class="h1">
          SURVIVAL RATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Survival after diagnosis with a primary brain or other CNS tumor varies considerably, depending on the age of the child and the type of tumor. Based on data from the Central Brain Tumor Registry of the United States (CBTRUS; 2015 to 2019), pituitary and nerve sheath tumors were the histologic groups with the highest survival rates after diagnosis, whereas embryonal tumors and malignant gliomas had the lowest survival rates after diagnosis [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The prognosis of the following specific CNS tumors that occur in children are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pilocytic astrocytoma (see
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors", section on 'Pilocytic astrocytoma'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant gliomas (see
         <a class="medical medical_review" href="/z/d/html/5229.html" rel="external">
          "Diffuse intrinsic pontine glioma"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medulloblastoma (see
         <a class="medical medical_review" href="/z/d/html/88801.html" rel="external">
          "Treatment and prognosis of medulloblastoma", section on 'Prognosis and genetic risk'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Craniopharyngioma (see
         <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">
          "Craniopharyngioma", section on 'Prognosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ependymoma (see
         <a class="medical medical_review" href="/z/d/html/5224.html" rel="external">
          "Intracranial ependymoma and other ependymal tumors", section on 'Prognosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal brainstem glioma (see
         <a class="medical medical_review" href="/z/d/html/5191.html" rel="external">
          "Focal brainstem glioma", section on 'Prognosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Germ cell tumors (see
         <a class="medical medical_review" href="/z/d/html/5199.html" rel="external">
          "Intracranial germ cell tumors"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intradural nerve sheath tumors, such as schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors (see
         <a class="medical medical_review" href="/z/d/html/5196.html" rel="external">
          "Intradural nerve sheath tumors", section on 'Prognosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meningioma (see
         <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">
          "Management of known or presumed benign (WHO grade 1) meningioma", section on 'Outcomes and prognosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15692.html" rel="external">
          "Management of atypical and malignant (WHO grade 2 and 3) meningioma", section on 'Prognosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spinal cord tumors (see
         <a class="medical medical_review" href="/z/d/html/5227.html" rel="external">
          "Spinal cord tumors"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberous sclerosis (see
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features", section on 'Presentation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other uncommon brain tumors (see
         <a class="medical medical_review" href="/z/d/html/5202.html" rel="external">
          "Uncommon brain tumors"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – In the United States, the estimated incidence of childhood primary nonmalignant and malignant central nervous system (CNS) tumors is approximately 6 cases per 100,000 population. Somewhat lower incidence rates are reported in other parts of the world.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States, primary malignant CNS tumors are the second most common childhood malignancies after hematologic malignancies and are the most common pediatric solid organ tumor  (
         <a class="graphic graphic_table graphicRef99680" href="/z/d/graphic/99680.html" rel="external">
          table 1
         </a>
         ). CNS tumors are a leading cause of cancer death in children 0 through 14 years. (See
         <a class="local">
          'Incidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – CNS tumors are classified according to histology and molecular parameters. The most common tumor types in children include gliomas (particularly pilocytic astrocytomas) and medulloblastomas  (
         <a class="graphic graphic_figure graphicRef70767" href="/z/d/graphic/70767.html" rel="external">
          figure 1
         </a>
         ). The distribution varies with age  (
         <a class="graphic graphic_figure graphicRef61480" href="/z/d/graphic/61480.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'World Health Organization classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distribution
         </strong>
         – The location of the tumor impacts the clinical presentation. Brain tumors account for approximately 90 percent of all CNS tumors, and the remaining CNS tumors are found in the spinal cord and cranial nerves. Approximately one-third to one-half of CNS tumors in children are located in the posterior fossa  (
         <a class="graphic graphic_figure graphicRef81514" href="/z/d/graphic/81514.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="local">
          'Distribution by site'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Although the etiology of most childhood CNS tumors remains unknown, two established risk factors for the development of a CNS tumor in children include exposure to ionizing radiation and genetic predisposition. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Survival time after diagnosis with primary brain or other CNS tumor varies considerably, depending on the age of the child and the tumor type. (See
         <a class="local">
          'Survival rates'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20:iv1.
          </a>
         </li>
         <li class="breakAll">
          Central Brain Tumor Registry of the United States. 2018 CBTRUS Fact Sheet. Available at: www.cbtrus.org/factsheet/factsheet.html.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrom QT, Price M, Neff C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol 2022; 24:v1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makino K, Nakamura H, Yano S, et al. Population-based epidemiological study of primary intracranial tumors in childhood. Childs Nerv Syst 2010; 26:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AIRTUM Working Group, CCM, AIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 2013; 37:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaatsch P, Rickert CH, Kühl J, et al. Population-based epidemiologic data on brain tumors in German children. Cancer 2001; 92:3155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobes M, Shadbolt B, Khurana VG, et al. A multicenter study of primary brain tumor incidence in Australia (2000-2008). Neuro Oncol 2011; 13:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YL, Lo WC, Chiang CJ, et al. Incidence of cancer in children aged 0-14 years in Taiwan, 1996-2010. Cancer Epidemiol 2015; 39:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrom QT, de Blank PM, Kruchko C, et al. Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol 2015; 16 Suppl 10:x1.
          </a>
         </li>
         <li class="breakAll">
          Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD 2019. Available at: https://seer.cancer.gov/csr/1975_2016/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4:iv1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou D, Zhang Y, Liu H, et al. Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005. Pediatr Neurosurg 2008; 44:97.
          </a>
         </li>
         <li class="breakAll">
          Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000, Bleyer A, O’Leary M, Barr R, Ries LAG (Eds), National Cancer Institute, NIH Pub. No. 06-5767, Bethesda, MD 2006.
         </li>
         <li class="breakAll">
          Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021; 23:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JC, Siffert J, Hukin J. Clinical manifestations of childhood ependymoma: a multitude of syndromes. Pediatr Neurosurg 1998; 28:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PE, Oleszek JL, Clayton GH. Pediatric spinal cord tumors and masses. J Spinal Cord Med 2007; 30 Suppl 1:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:5287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 2015; 373:2336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hjorth S, Hemmingsen CH, Bénévent J, et al. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers. Am J Epidemiol 2021; 190:2487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng S, McLaughlin JR, Brown MC, et al. Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada. Br J Cancer 2023; 129:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oksuzyan S, Crespi CM, Cockburn M, et al. Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California. Cancer Epidemiol 2013; 37:402.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6251 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18074355" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Trends in childhood cancer incidence in the U.S. (1992-2004).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30445539" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30445539" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36196752" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20349186" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Population-based epidemiological study of primary intracranial tumors in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23585445" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Italian cancer figures, report 2012: Cancer in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11753995" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Population-based epidemiologic data on brain tumors in German children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21727214" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A multicenter study of primary brain tumor incidence in Australia (2000-2008).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25599927" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Incidence of cancer in children aged 0-14 years in Taiwan, 1996-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25542864" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25542864" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26511214" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230922" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230922" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18230922" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34185076" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9693331" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical manifestations of childhood ependymoma: a multitude of syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17874681" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pediatric spinal cord tumors and masses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079138" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26580448" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Germline Mutations in Predisposition Genes in Pediatric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34017981" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37165200" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23562044" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
